Allgaier H P, Deibert P, Blum U, Spangenberg H C, Moser E, Blum H E
Abteilung Innere Medizin II, Medizinische Universitätsklinik, Freiburg in Breisgau.
Schweiz Med Wochenschr. 1996 Nov 16;126(46):1984-94.
The therapeutic modalities in patients with hepatocellular carcinoma (HCC) depend on the number, size and location of the lesions as well as the stage of the underlying liver disease and the physical condition of the patient. In patients with small and solitary lesions, resection, liver transplantation and in some cases percutaneous ethanol injection (PEI) can be curative. In more advanced stages of the disease with larger or multiple lesions, PEI and/or transarterial chemotherapy with or without embolization (TACE or TAC) can slow the progression of the disease. In disseminated disease, a radiotherapeutic approach can be taken in selected cases. The therapeutic strategy in patients with HCCs should be individualized, frequently involving a combination of therapeutic modalities. In contrast to the earlier dismal prognosis, for most HCC patients there is today a therapeutic strategy that results in prolongation of life and in some cases even cure.
肝细胞癌（HCC）患者的治疗方式取决于病变的数量、大小和位置，以及潜在肝脏疾病的阶段和患者的身体状况。对于小的孤立性病变患者，手术切除、肝移植以及在某些情况下经皮乙醇注射（PEI）可能治愈疾病。在疾病的更晚期，病变较大或为多发时，PEI和/或经动脉化疗（伴或不伴栓塞，即TACE或TAC）可减缓疾病进展。对于播散性疾病，在特定病例中可采用放射治疗方法。HCC患者的治疗策略应个体化，通常需要多种治疗方式联合应用。与早期令人沮丧的预后不同，如今大多数HCC患者都有可延长生命甚至在某些情况下实现治愈的治疗策略。
